Intervet Inc.

Akzo Nobel N.v.

Intervet International B.v.

Maarten Hendrik Witvliet

Melanie Sno

Vicky Fachinger

Antonius Arnoldus Christiaan Jacobs

Ruud Philip Antoon Maria Segers

Theodorus Jansen

Petrus Johannes Maria Nuijten

Huchappa Gowda Jayappa

Erwin Van Den Born

Selma Marianne Hensen

Keith Redhead

Christa Sibilla Drexler

Johanna Jacoba Elisabeth Bijlsma

Jozef Franciscus Maria Smeets

The present invention pertains to a vaccine to protect a pig against an infection with, the vaccine comprising an RTX toxin ofrecombinantly expressed by a baculovirus, and a pharmaceutically acceptable carrier.

Vaccine to protect a pig against

The present invention pertains to a vaccine comprising in combination non-replicating immunogen of porcine circo virus type 2 and live attenuated PRRS virus for use in prophylactically treating an animal against an infection with porcine circovirus type 2 (PCV2) and an infection with PRRS virus by administration of the vaccine into the dermis of the animal.

Vaccine for intradermal application against PCV2 and PRRS virus infection

The present invention pertains to a combination of a first vaccine comprising non-replicating immunogen of porcine circo virus type 2 (PCV2) and non-replicating immunogen of, and a second vaccine comprising live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating an animal against an infection with porcine circovirus type 2, an infection withand an infection with PRRS virus, by associated non-mixed administration of the first vaccine and the second vaccine to the animal. The invention also pertains to a kit-of-parts comprising the first and second vaccine and to a method of protecting an animal against such infections using these vaccines.

Vaccines containing swine pathogens for associated non-mixed use

The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.

Combination vaccine for swine

The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection byor PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of anantigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease byand PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.

Process for ready-to-use PCV/M.Hyo combination vaccine

The present invention pertains to a vaccine comprising in combination killed whole cell Lawsonia intracellularis bacteria and porcine circo virus 2 (PCV2) ORF2 protein for use in protecting a pig against an infection with Lawsonia intracellularis and PCV2 by an intradermal administration of the vaccine. The invention also pertains to a method to protect a swine against an infection with Lawsonia intracellularis bacteria and PCV2.

Vaccine against Lawsonia intracellularis and porcine circovirus 2

The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.

Vaccine against porcine circo virus type 2

The present invention relates to the use of an immunogenic dose of immunogenic material ofand an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.

[object Object]

The present invention relates to live attenuatedstrains comprising a first attenuating mutation, that are not capable of making functional RecA. The invention also relates to these bacteria for use in vaccines. Furthermore, the invention relates to vaccines based upon these bacteria, to the use of such bacteria in the manufacture of vaccines and to methods for the preparation of such vaccines.

The present invention provides NAD-independent Mycoplasma synoviae of strain MS1. The invention also refers to microbiological cultures comprising Mycoplasma synoviae of this strain. Next to this, the invention refers to live vaccines derived from these strains, for the protection of poultry against Mycoplasma synoviae infection. Furthermore, the invention provides methods for the preparation of such vaccines. Also, the use of NAD-independent Mycoplasma synoviae strains for the preparation of live vaccines for the protection of poultry against Mycoplasma synoviae infection is disclosed.

Growing community of inventors

Oostrum, Netherlands

Maarten Hendrik Witvliet